Feasibility and safety of remdesivir in SARS‐CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation

Abstract

RDV therapy is safe and clinically feasible in renal transplant recipients as seen in our cohort. Larger clinical registries and randomized clinical trials should be conducted to further explore the efficacy in transplant recipients.